Apr 6, 2013 by Dave Williamson and Max MacalusoFinal Four Stocks: Abbott Labs vs. AbbVieThe Motley Fool's exclusive health-care stock tournament moves closer to crowning a champion.
Apr 6, 2013 by Dave Williamson and Max MacalusoMedicare Advantage "Armageddon" Averted 13 million seniors are saved, and insurance stocks soar.
Apr 4, 2013 by Dave WilliamsonConcerns Swirl Over Critical Drug LaunchCan this pharmaceutical company shake lingering safety profile fears?
Apr 3, 2013 by Dave WilliamsonIs This Biotech an Undiscovered Gem?Could this company be a diamond in the rough for investors?
Apr 3, 2013 by Dave WilliamsonIs This Bidding War Almost Over?Is this pharmaceutical finally close to being acquired?
Apr 3, 2013 by Dave Williamson and Max MacalusoHealth Care's Elite Eight Stocks: Celgene vs. GileadThe Motley Fool's exclusive healthcare stock tournament moves closer to crowning a champion.
Apr 3, 2013 by Dave Williamson and Brenton FlynnHealth Care's Elite Eight Stocks: Abbott Labs vs. SanofiThe Motley Fool's exclusive healthcare stock tournament moves closer to crowning a champion.
Apr 2, 2013 by Dave WilliamsonIs This Really Big Pharma's Next Acquisition?Where did all this buyout interest come from?
Apr 1, 2013 by Dave Williamson and Brenton FlynnHealth Care's Elite Eight Stocks: AstraZeneca vs. AbbVieThe Motley Fool's exclusive health-care stock tournament moves closer to crowning a champion.
Mar 31, 2013 by Dave Williamson and Brenton FlynnHealth Care's Sweet 16 Stocks: Gilead vs. AmgenThe Motley Fool's exclusive bracket decides what health-care stock is the best investment
Mar 31, 2013 by Dave Williamson and Max MacalusoHealth Care's Sweet 16 Stocks: Celgene vs. BiogenThe Motley Fool's exclusive health-care stock bracket crowns the best investment of the sector.
Mar 30, 2013 by Dave Williamson and Brenton FlynnHealth Care's Sweet 16 Stocks: Johnson & Johnson vs. PfizerThe Motley Fool's exclusive bracket determines the top health-care stock.
Mar 30, 2013 by Dave Williamson and Max MacalusoHealth Care's Sweet 16 Stocks: Novartis vs. Bristol-Myers SquibbThe Motley Fool's health-care bracket finds out which stock is the best investment.
Mar 30, 2013 by Dave WilliamsonApril's Must-Watch Biotech StockSarepta's critical Duchenne muscular dystrophy drug eteplirsen is up for FDA accelerated approval in April.
Mar 26, 2013 by Dave WilliamsonSo Far, So Good for Gilead's BlockbusterSofosbuvir is safe enough to continue its phase 3 trial.
Mar 26, 2013 by Dave WilliamsonIs Anything Left for Ziopharm Investors?Is there any hope for Ziopharm after this utter collapse?
Mar 26, 2013 by Dave WilliamsonEli Lilly's Boom-or-Bust PotentialCan Eli Lilly's pipeline arsenal beat back losses from a very steep patent cliff on the horizon?
Mar 25, 2013 by Dave WilliamsonUnited Therapeutics Can't Stop Getting RejectedAnother FDA rejection for United Therapeutics?
Mar 25, 2013 by Dave Williamson2 Biotechs' Critical Patent ShowdownGilead wins the round, but the war continues.
Mar 25, 2013 by Dave Williamson2 Big Risks Threatening Celgene2 big risks every Celgene investor needs to be aware of.
